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Abstract
Aim: The aim of this study is to replicate both clinical and histological presentation of bisphosphonate induced 
osteonecrosis of the jaws (BONJ) in an animal model of the disease state. Successful recapitulation of a BONJ-
like indication in an animal model will be useful for studying pathogenesis, as well as prevention and treatment 
strategies for BONJ. 
Materials and Methods: Eighty (80) rats were prospectively and randomly divided into two groups; control group(40) 
and study group(40). All animals in study group, injected with a dose of 1 mg/kg dexamethasone (DX) subcutane-
ously on day 7, 14, or 21; and 1, 2, or 3 doses of 7.5 µg/kg zoledronic acid (ZA) subcutaneously administered to coin-
cide with the last day of DX. Half of the animals from each group underwent extraction of the left mandibular molars 
and the remaining animals underwent extraction of the left maxillary molars under pentobarbital-induced general 
anesthesia. All animals were euthanized twenty-eight (28) days following tooth extractions. 
Results: The amount of new bone trabecules  as significantly decreased in bisphosphonate-dexamethasone (BP-
DX) treated sockets. Difference between both groups was found statistically significant (p=0,0001). There’s no 
foreign body reaction in sockets of both groups and no significance difference observed for fibrosis (p=0,306). 
The necrosis scores were significantly higher in BP-DX treated sockets (p=0,015). The inflamation scores were 
significantly higher for study group (p=0,0001). 
Conclusion: This study provides preliminary observations for the development of an animal model of BONJ. But 
we think that there is need for other studies have only BP treated group and larger study population. 
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Introduction
Bisphosphonates (BPs)  are a group of medication used 
in clinical settings for over thirty years to inhibit bone 
resorption (1).  They are used to treat patients with mul-
tiple myeloma, metastatic disease of the skeleton  (2) 
and they are also effective in patients with Paget’s dis-
ease of bone and osteoporosis (3).
A recognized side effect of BP is osteonecrosis of 
jaws (BONJ) (4,5). Overwhelmingly, the majority of 
reported BONJ cases are associated with infused ni-
trogen containing bisphosphonates (zoledronic acid or 
pamidronate) used for patients with multiple myeloma 
or breast cancer.6 While the overall incidence of this 
condition among patients at risk has yet to be defined, 
a recent report places it between 1% and 10%.  A full 
understanding of the natural history of the condition, as 
well as risk factors associated with it, is evolving. Nev-
ertheless, it appears that the duration of intravenous BP 
therapy, dental manipulation, patient age and the site of 
bone (mandible versus maxilla) all contribute to the in-
creased likelyhood of a patient developing BONJ (6,7). 
While BONJ appears to be self-limiting, patients may 
suffer from bothersome necrotic lesions as well as pain-
ful ulcerations overlying areas of necrosis. 
The lesions usually occur after dental extractions or 
oral trauma, but they also occur spontaneously with 
no history of surgical procedures, trauma, or radiation 
therapy (8,9).  Most of these patients were being treated 
with intravenous BPs to inhibit skeletal progression in 
late-stage cancer (4,9). Many of them had a history of 
malignancy, including multiple myeloma, breast carci-
noma, or prostate carcinoma. A definitive mechanism 
for this “bisphosphonate-associated osteonecrosis” has 
not yet been identified. 
BPs have a non-hydrolysable P–C–P bond and bind with 
hydroxyapatite of bone. Their ingestion by osteoclasts 
results in anti-bone-resorptive effects. By inhibiting 
bone resorption, BPs alter normal remodeling, which 
can reduce the mechanical properties of bone causing 
accumulation of areas of microdamage (10). Jawbones 
may be more affected, because of increased bone re-
modeling in the alveolar region (11,12).
In addition to their effects on osteoclasts, BPs also 
show antiangiogenic properties, which may play a role 
in bisphosphonate-related osteonecrosis (13,14). This is 
evidenced by significantly decreased angiogenesis in 
endothelial cells treated with zoledronate in vitro, with 
decreased endothelial cell proliferation, adhesion, and 
migration (13).
The aim of the study is to replicate both clinical and his-
tological presentation of BONJ in an animal model of 
the disease state. Successful recapitulation of a BONJ-
like indication in an animal model will be useful for 
studying pathogenesis, as well as prevention and treat-
ment strategies for BONJ.
Materials and Methods
We prepared the study protocol in consideration of pre-
liminary reports. 
Experimental animals
Eighty male Wistar rats (body weight 110-120 g, approx-
imately 5 weeks old) were purchased from DETAM (Is-
tanbul, Turkey). Rats were assigned to either the study 
group or the control group (n = 40 for each). Animals 
were acclimatized prior to the start of the study and any 
animal observed to be in poor condition was rejected 
from study inclusion. Rats were housed in cages pro-
vided with filtered air at a temperature of 70 °F ± 5° and 
50 ± 20% relative humidity. A 12 h light/dark cycle was 
maintained. Animals were fed with a standard diet of 
rat chow and watered ad libitum. All experiments were 
performed in accordance with the Guidelines for Ani-
mal Experiments of the Faculty of Medicine , Istanbul 
University, Istanbul, Turkey.  
Experimental methods and design
Eighty (80) rats were prospectively and randomly divid-
ed into two groups, control group (40) and study group 
(40). All animals in study group injected with a dose of 
1 mg/kg dexamethasone (DX) subcutaneously on day 0, 
7, or 14; and 1, 2, or 3 doses of 7.5 µg/kg zoledronic acid 
(ZA) subcutaneously, administered to coincide with the 
last day of DX. In the control group, physiological saline 
was injected into the same area. Rats were anesthetized 
before injection using diethyl ether.
Extractions were performed the day following the last 
injections. Half of the animals from each group under-
went extraction of the left mandibular molars and the 
remaining animals underwent extraction of the left 
maxillary molars with a dental explorer under pento-
barbital-induced general anesthesia. 
Five animals from study group and two animals from 
control group were excluded because these animals died 
before sacrification date. All animals were euthanized 
twenty-eight (28) days following tooth extractions. Jaws 
including the extraction site were resected. 
Histopathological observations
Bone samples were decalcified in 10% EDTA (pH 7.2) 
at 4 ºC for 21 days. Decalcified samples were embedded 
in paraffin using the standard method, and then a series 
of 5µ sections were prepared. Hematoxylin-eosin (HE)-
stained sections were observed using a light microscope 
(Eclipse E600; Nikon, Tokyo, Japan).
“Olympus Soft imaging system analySIS FIVE” system 
is used. Digital images are prepared under 400 magnifi-
cation and inflammation, necrosis, fibrosis and new bone 
regeneration are investigated. Inflammation and fibrosis 
have been given +(%1-30), ++(%30-60) or +++(>%60) 
scores according to their surface covering. Necrosis of 
tissue samples was noted as yes or no and was used to 
determine the percentage of animals with necrosis. For 
new bone regenaration if there’s no bone formation (-) , 
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%1-30 bone formation (+), %30-60 bone formation (++) 
and for >%60 (+++) scores are given. Additionaly for-
eign body reaction noted as present or absent.
Statistical analysis
We used + score for the data between 0-30, ++ score 
for the data between 31-60 and +++ score for the data 
higher than 60. So we transformed the continues data to 
non-continues data. That’s why we prefered chi-square 
test.
The significance of differences between both groups 
was evaluated with a chi-square test. A p-value of 0.05 
was considered statistically significant for all tests. 
Results
In general, animals tolerated the procedure well and 
demonstrated good hemostasis and rapid recovery from 
anesthesia. Gross evidence of extraction site healing 
was seen in the majority of both groups in 28 days. 
Fig 1. The amount of new bone trabeculaes was signifi-
cantly decreased in BP-DX treated sockets (Study group, 
H&E x200).
Fig 2. Fistula formation over the necrotic bone area and 
granulation tissue under the epithelium (Study group, 
H&E x400). 
Fig 3. Absess center in the granulation tissue around the 
extraction socket (Study group, H&E  x200).
 Study Group Control Group  
(-) 10 28,60% 0 0,00%  
New Bone (+) 16 45,70% 0 0,00%  
Formation (++)  9 25,70% 18 47,40% 2:48,96 
(+++)  0  0,00% 20 52,60% P=0,0001 
    Inflammation 
(-)  1  2,90% 16 42,10% 
(+) 16 45.70% 18 47,40% 
(++) 15 42,90% 4 10,50% 2:22,64 
(+++)  3  8,60%  0 0,00% P=0,0001 
Necrosis No 14 40,00% 26 68,40% 
2:5,94 
Yes 21 60,00% 12 31,60% P=0,015 
(+) 17 48,60% 24 63,20%  
Fibrosis (++) 17 48,60% 14 36.80% 2:2,37 
(+++)  1  2,90%  0 0,00% P=0,306 
Foreign Body 
Reaction (-) 35 100,00% 38 100,00%  
Table 1. Statistical observations for study and control groups.
- (%0), + (%1-30), ++ (%30-60), +++ (>%60) 
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28 days after tooth extraction, resorption of residual in-
terdental bone septum by osteoclasts as well as forma-
tion of new bone trabeculaes were viewed in sockets of 
both groups. However, the amount of new bone trabecu-
laes was significantly decreased in BP-DX treated sock-
ets (Fig. 1). This difference between both groups was 
found statistically significant (p=0,0001).
There is no foreign body reaction in sockets of both 
groups and no significant difference was observed for 
fibrosis(p=0,306). Necrosis scores were significantly 
higher in BP-DX treated sockets(p=0,015) (Fig. 2). In-
flamation scores were significantly higher for BP-DX 
treated group (p=0,0001). By day 28, the intensity of 
the inflammatory infiltrate in study group was mild to 
moderate (Fig. 3) ( Table 1).
Discussion
In the present study we aimed to  replicate both clini-
cal and histological presentation of BONJ in an animal 
model of the disease state. Successful recapitulation of 
a BONJ-like indication in an animal model will be use-
ful for studying pathogenesis, as well as prevention and 
treatment strategies for BONJ.
There have been several recent reports of BONJ occur-
ring after oral surgery (e.g., tooth extraction) in patients 
(especially cancer patients) undergoing long-term BP 
treatment. 
Our primary interest in bisphosphonates focused on the 
patient population with multiple myeloma, thus we used 
cycles of ZA and included a concomitant course of DX 
to mimic the regimen typically given to patients with 
multiple myeloma. 
In previous histological studies on healing of extrac-
tion sockets in normal rats, it has been found that new 
bone begins to form on the floor of the extraction socket 
about 2 days after extraction, and the extraction socket 
becomes filled with newly formed bone 14 days after 
extraction (15,16).  In present study; 28 days post-ex-
traction, complete epithelialization of the extraction 
sites was observed only in control animals. In contrast, 
clinical and histological evidence of delayed healing, as 
manifested by exposed bone or ulceration, was seen in 
many of  ZA/DX-treated animals.
Hikita et al. (17) observed that healing of the extraction 
socket was delayed in rats with impairment of bone re-
sorption caused by inhibition of osteoclast function be-
gan just after tooth extraction as a result of the alendro-
nate pretreatment. In studies of the effect of BPs on bone 
formation, Yamamoto et al. (18) and Tabuchi et al. (19) 
found that osteoclasts appeared prior to osteoblasts, and 
that activation of osteoclasts influenced the subsequent 
promotion of bone formation in various ways. These re-
sults suggest that inhibition of osteoclast formation just 
after extraction is related to delayed initial healing. In 
present study; the amount of new bone trabeculaes was 
significantly decreased in BP-DX treated sockets.
Ulcerative changes were present in the majority of ZA/
DX-treated rats. Reid et al. propose that damage to the 
alveolus initiated by procedures or other trauma results 
in the local release of bound bisphosphonates into the 
surrounding tissue. The released bisphosphonates are 
toxic to the overlying epithelium and can result in in-
hibition of proliferation and wound healing (20). Ad-
ditional study is clearly needed to clarify the process 
which underlies ulcerative changes.
The character of the inflammatory infiltrate differ ap-
preciably between control and study groups.  By day 
28, the intensity of the inflammatory infiltrate in study 
group was mild to moderate. 
Hikita et all reported that if  BP first administered 
just after tooth extraction, effects processes such as 
hypocalcemia first appeared during the later stages of 
the healing (17). However, in the present study admin-
istration of BP prior to tooth extraction, such that the 
tooth was extracted under the active pharmacological 
influence of BP, caused initial healing of the extraction 
socket to be delayed. These data show that the timing of 
BP administration can strongly affect the healing of the 
extraction socket.
Our results well matched with the results of another 
study focused on the multiple myeloma patients. This 
study had similar doses for DX-BP and similar results 
reported for osteonecrosis (21).
This study provides preliminary observations for the 
development of an animal model of BONJ. Successful 
recapitulation of a BONJ-like indication in an animal 
model will be useful for studying pathogenesis, as well 
as prevention and treatment strategies for BONJ. We 
belive that we recapulate the BONJ-like indication in 
an animal model. But there is need for more studies 
with other BP and DX doses, timings and  larger study 
groups to define the DX and BP doses and timings for 
prevention of BONJ in multiple myeloma population 
and effective evaluation of treatment options for BONJ.
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